ArticleTherapeutic advances in musculoskeletal disease2026
Serum interleukin-8 levels relate to disease activity in patients with rheumatoid arthritis.
Article in Therapeutic advances in musculoskeletal disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Interleukin 8 (IL-8) is a chemokine involved in the pathogenesis of rheumatoid arthritis (RA). However, the clinical significance of its circulating levels remains poorly defined, partly due to technical challenges in measuring IL-8 in serum. Consequently, data on the relationship between serum IL-8 concentrations and specific disease manifestations in RA are limited. Objective: In this study, we aimed to investigate the associations between serum IL-8 levels and clinical, serological, and cardiovascular features in patients with RA. Design: Cross-sectional study. Methods: A total of 216 RA patients were recruited. They underwent comprehensive evaluations, including disease-related characteristics and disease activity indices. Moreover, complete lipid profile, insulin resistance indices, metabolic syndrome criteria, and carotid ultrasound for carotid stiffness, intima-media thickness and carotid plaque detection were assessed. The SCORE2 -Systemic Cardiovascular Risk Estimation- was also calculated. IL-8 serum levels were measured using Simoa (Single Molecule Array) technique. A multivariable linear regression analysis was performed to examine the associations between disease characteristics and IL-8. Results: C-reactive protein and IL-6 were significantly associated with higher IL-8 levels after multivariable adjustment. Likewise, disease activity scores were independently and positively correlated with higher serum IL-8 concentrations after adjustment for covariates. In contrast, rheumatoid factor and anti-citrullinated protein antibodies positivity showed no association with IL-8 levels. With respect to cardiovascular features, higher SCORE2 and carotid intima media thickness values were positively related to increased IL-8 concentrations. Conclusion: Serum IL-8 levels are independently and positively associated with disease activity scores in patients with RA. These findings suggest that IL-8 may have potential as a biomarker in this population but requires prospective validation and comparison with standard markers. The observed relationship between IL-8 levels and the SCORE2 risk calculator suggests a potential association between IL-8 and cardiovascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.